Elsevier

Seminars in Oncology

Volume 43, Issue 2, April 2016, Pages 199-200
Seminars in Oncology

Chronic lymphocytic leukemia: recent progress and current challenges

https://doi.org/10.1053/j.seminoncol.2016.02.001Get rights and content

References (0)

Cited by (3)

  • Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience

    2019, Clinical Lymphoma, Myeloma and Leukemia
    Citation Excerpt :

    Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed leukemia in the Western world, with > 20,000 estimated new cases in the United States in 2018.1 Treatment with a chemotherapy backbone in combination with an anti-CD20 antibody has been the standard treatment approach for CLL in the past decades.2,3 However, more recently the treatment strategy has moved toward a “chemo-free” approach with the introduction of novel targeted agents such as Bruton tyrosine kinase inhibitors (ibrutinib), phosphoinositide 3-kinase inhibitors (idelalisib and duvelisib), and the B-cell lymphoma 2 antagonist venetoclax.4-7

  • Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?

    2016, Clinical Lymphoma, Myeloma and Leukemia
    Citation Excerpt :

    In addition, molecular delineation of targeted therapies' resistance patterns will obviously help to design rationale salvage strategies based on alternative small molecules or cellular therapy.72 Rather than competing interventions, BCRi, other molecules and allotransplantation should be considered as complementary treatments in the management of CLL associated with the del(17)/TP53 mutation.81,82 In this regard, for example, BCRi may be an excellent treatment to “cross the bridge” from relapsed/refractory disease to transplantation.

View full text